Drug pricing
Featured Topics
Lead story
Other featured articles
-
Federal 340B Drug Pricing Policies Need Reform to Realize Potential
USC Schaeffer study finds Federal 340B Drug Pricing Program oversight needs tightening to ensure discounts reach the right safety-net providers and patients
Posted in -
Getting It Right: Drug Pricing Reform That Works for Patients and the Medicare Program
As Congress narrows in on prescription drug pricing reform, what policy changes should be prioritized? Join Schaeffer Center and the Alliance for Aging Research to hear from a policymaker at the center of the debate in Congress, an expert in healthcare policy research, and a leading advocate for older adults.
Posted in -
Biosimilars Competition Helps Patients More Than Generic Competition
Schaeffer Center Co-Director Dana Goldman argues that well-intended proposals to have the government intervene and “incentivize” biosimilar uptake may result in less price competition, not more.
Posted in -
Federal Government Should Advise on Drug Negotiations, Not Run Them
Schaeffer Center experts Karen Mulligan and Darius Lakdawalla argue that the Department of Health and Human Services should help advice drug price negotiations instead of running them.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug pricing
Our Work In Drug pricing
-
Money for the Infrastructure Bill is Coming at the Expense of Medicare Part D
The $1 trillion infrastructure bill will leave a lot of chronically ill people by the side of the road.
Categorized in -
A Framework for Categorizing and Analyzing Prescription Drug Pricing Reform Options
Schaeffer Initiative experts present a framework for categorizing and analyzing a wide range of proposed policy reforms for prescription drug pricing.
Categorized in -
Government Regulated or Negotiated Drug Prices: Key Design Considerations
Americans pay much higher prices for brand drugs than do people who live in other industrialized nations. Most Americans—79 percent—consider U.S. prescription drug prices to be unreasonable, with almost 3 in 10 reporting they go without prescribed medications because of cost. With 70 percent of Americans reporting that lowering drug costs is their highest healthcare priority, the Congress and the Biden Administration are considering how to lower US drug prices
-
Multi-Cancer Blood Tests Can Reduce Late-Stage Cancer Diagnosis in Black and Latino Patients
A new white paper published by the USC Schaeffer Center focuses on the potential benefit of multi-cancer early detection (MCED) blood-based tests to reduce disparities in late-stage cancer diagnosis among minority populations.
Categorized in -
Drug Rebates in Medicare Part D
On July 27, the USC-Brookings Schaeffer Initiative for Health Policy will host a webinar to discuss how the increasing reliance on rebates burdens many Medicare patients and policy solutions.
Categorized in -
Reducing Racial Disparities in Early Cancer Diagnosis With Blood-Based Tests
A new white paper published by the USC Schaeffer Center focuses on multi-cancer, early detection, (MCED) blood-based tests as one solution to reduce disparities in late-stage cancer diagnosis among minority populations.
Categorized in